Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Neurocrine biosciences - You Need To See This

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals (NASDAQ:IONS) products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocri

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022

Neurocrine Biosciences Earnings Perspective: Return On Capital Employed

Neurocrine Biosciences Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60 million, a 0.45% change since Q4.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Neurocrine Biosciences: Q1 Earnings Insights

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET

Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

What 8 Analyst Ratings Have To Say About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:

Where Neurocrine Biosciences Stands With Analysts

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking Into Neurocrine Biosciences's Return On Capital Employed

Looking Into Neurocrine Biosciences's Return On Capital Employed

Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.

Why Neurocrine Biosciences Are Trading Higher Today?

Why Neurocrine Biosciences Are Trading Higher Today?

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported

Recap: Neurocrine Biosciences Q4 Earnings

Recap: Neurocrine Biosciences Q4 Earnings

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine Biosciences reported an EPS of $0.04.

A Preview Of Neurocrine Biosciences's Earnings

A Preview Of Neurocrine Biosciences's Earnings

Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that Neurocrine Biosciences will likely report an Earnings Per Share (EPS) of $0.52.

Analyst Ratings For Neurocrine Biosciences

Analyst Ratings For Neurocrine Biosciences

Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:

1

Organisations

Willis Towers Watson

Ionis Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

374,174 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play